Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

Rhea-AI Summary

Shuttle Pharmaceuticals (NASDAQ: SHPH) on March 26, 2026 announced a major expansion of its molecule.ai platform, adding new predictive and generative models and a preview of an autonomous, multi-agent AI system for scientific workflows.

The update enables multi-step reasoning, multimodal data ingestion, and prioritization of gene–disease and compound–target relationships to accelerate early therapeutic discovery and reduce manual research effort.

News Market Reaction – SHPH

-22.87% 4.4x vol

37 alerts

-22.87% News Effect

+22.3% Peak Tracked

-44.8% Trough Tracked

-$2M Valuation Impact

$5.26M Market Cap

4.4x Rel. Volume

On the day this news was published, SHPH declined 22.87%, reflecting a significant negative market reaction. Argus tracked a peak move of +22.3% during that session. Argus tracked a trough of -44.8% from its starting point during tracking. Our momentum scanner triggered 37 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $5.26M at that time. Trading volume was very high at 4.4x the daily average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $0.6633 Vol: Volume 120,819 is 1.52x t...

high vol

$0.6633 Last Close

Volume Volume 120,819 is 1.52x the 20-day average of 79,353, indicating elevated trading activity pre-announcement. high

Technical Shares at 0.8963 are trading below the 200-day MA of 2.71 and sit far below the 13.63 52-week high.

Peers on Argus

Momentum scanner shows three peers (AKAN, CPHI, UPC) all moving down, while the ...

3 Down

Momentum scanner shows three peers (AKAN, CPHI, UPC) all moving down, while the scanner flags SHPH’s direction as up. This mix, plus no same-day peer news, points to stock-specific dynamics rather than a coordinated sector move.

Previous AI Reports

4 past events · Latest: Jan 13 (Positive)

Same Type Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
Jan 13	AI platform update	Positive	+6.3%	Highlighted Utah AI refill pilot and relevance to Molecule.ai platform.
Oct 21	AI acquisition LOI	Positive	-7.2%	Definitive LOI to acquire Molecule.ai and report Phase 2, orphan status.
Oct 10	AI LOI execution	Positive	-13.9%	Non-binding LOI to acquire Molecule.ai and extend AI discovery features.
Oct 09	AI market entry	Positive	-13.9%	Non-binding LOI to enter AI pharmaceutical market via Molecule.ai.

Pattern Detected

AI-tagged news has produced mixed reactions, with one positive move and several sharp declines, and an average move of -7.16% after such announcements.

Recent Company History

Over the past several months, Shuttle Pharmaceuticals has repeatedly highlighted its shift toward AI-driven discovery centered on the Molecule.ai platform. Multiple LOIs and acquisition announcements in October 2025 framed Molecule.ai as a strategic pivot. A January 2026 AI update tied the platform to real-world regulatory changes. Today’s AI workflow announcement continues that narrative of deepening Molecule.ai capabilities rather than introducing a new strategic direction.

Historical Comparison

-7.2% avg move · Past AI-tagged releases around Molecule.ai averaged a -7.16% move, with three declines and one gain,...

AI

-7.2%

Average Historical Move AI

Past AI-tagged releases around Molecule.ai averaged a -7.16% move, with three declines and one gain, underscoring historically volatile reactions to similar AI strategy updates.

AI news has progressed from initial LOIs with Molecule.ai in October 2025, to definitive acquisition steps and integration with clinical programs, and then to broader positioning of Molecule.ai as a scalable AI drug-discovery platform.

Market Pulse Summary

The stock dropped -22.9% in the session following this news. A negative reaction despite an upbeat A...

Analysis

The stock dropped -22.9% in the session following this news. A negative reaction despite an upbeat AI workflow update would fit a history where several AI-tagged announcements produced declines, with an average move of -7.16%. In that context, pressure could reflect market concerns about execution, prior operating losses, or financing needs discussed in recent SEC filings rather than the technical merits of the AI agent system alone. Historical volatility around Molecule.ai milestones highlights the potential for sharp sentiment reversals.

Key Terms

autonomous ai agent, multimodal data, multi-step reasoning, multi-agent orchestration, +1 more

5 terms

autonomous ai agent technical

"preview of its next-generation autonomous AI agent system, built on top"

An autonomous AI agent is a software

multimodal data technical

"The agents will be capable of ingesting multimodal data, leveraging integrated"

Multimodal data is information that combines different types of sources—such as numbers, written reports, photos, audio, and sensor readings—into a single view. For investors it matters because blending these types is like looking at a company with both a microscope and a wide-angle lens: it can reveal risks, trends, or opportunities that a single type of data would miss, improving decision-making, forecasting, and due diligence.

multi-step reasoning technical

"move beyond traditional single-step predictions by enabling multi-step reasoning"

Multi-step reasoning is the process of reaching a conclusion by linking a series of logical steps, where each step depends on the previous one—like following a recipe where each instruction must be completed in order to get the final dish. For investors, it matters because forecasts, risk assessments and regulatory interpretations often require chaining facts, assumptions and calculations; errors or missing steps can turn a plausible-looking conclusion into a bad decision.

multi-agent orchestration technical

"enabling multi-step reasoning and multi-agent orchestration across complex"

A coordinated system where multiple independent software 'agents' — small programs that carry out specific tasks — work together to complete complex workflows and make decisions. Like a team of specialized assistants passing notes and delegating chores, this arrangement can speed up operations, cut costs, and enable new products or services; investors watch it because it affects a company’s efficiency, competitive edge, and potential for automation-related growth or risk.

frontier ai models technical

"autonomous AI agent system, built on top of frontier AI models. This system"

Frontier AI models are the most advanced artificial intelligence systems that push the limits of what machines can understand, generate or decide, built by training on massive amounts of data and powerful computing. They matter to investors because they can create new products, cut costs, or reshape markets—like a prototype race car that proves a technology’s potential—while also concentrating competitive advantage and regulatory or ethical risks that can affect company value and future returns.

AI-generated analysis. Not financial advice.

Gaithersburg, Maryland--(Newsfile Corp. - March 26, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), today announced a major advancement to its molecule.ai platform, significantly expanding its capabilities in therapeutic discovery and positioning the Company at the forefront of AI-driven drug development.

The latest release introduces new models that enable users to more effectively evaluate, prioritize, and advance therapeutic candidates. By integrating enhanced predictive and generative capabilities into a unified platform, Shuttle Pharma is accelerating the transition from fragmented data analysis toward a scalable, end-to-end solution for therapeutic development.

This update marks a critical evolution for AI-driven drug discovery: from standalone model outputs to a more sophisticated reasoning system. The platform can now identify and prioritize relationships between genes and disease pathways and predict compound interactions with specific biological targets. Combined with existing molecular prediction tools, molecule.ai delivers a more connected and efficient framework for evaluating therapeutic opportunities-driving faster, higher-confidence decision-making earlier in the discovery lifecycle.

In addition, the Company unveiled a preview of its next-generation autonomous AI agent system, built on top of frontier AI models. This system is designed to move beyond traditional single-step predictions by enabling multi-step reasoning and multi-agent orchestration across complex scientific workflows. The agents will be capable of ingesting multimodal data, leveraging integrated tools, and executing discrete research tasks-dramatically reducing manual effort and increasing throughput for research teams.

"This release represents a meaningful step toward fully autonomous therapeutic discovery," said Chris Cooper, Chief Executive Officer of Shuttle Pharma. "We are not just improving model performance-we are redefining how drug development workflows are executed. By integrating reasoning, prediction, and automation into a single platform, molecule.ai has the potential to materially reduce timelines, lower costs, and increase the probability of success across the development pipeline. We believe this positions Shuttle Pharma to play a leading role in the next generation of AI-powered biopharma innovation."

As Shuttle Pharma continues to expand molecule.ai's capabilities, the Company remains focused on building a scalable platform that can unlock new therapeutic opportunities, improve development efficiency, and create long-term value for shareholders.

About Shuttle Pharma

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) owns a pharmaceutical software artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai platform helps researchers explore the chemical space more efficiently, evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements concerning the development and future capabilities of the Molecule.ai platform. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including our ability to realize the anticipated benefits from the Molecule.ai platform, risks related to the acquisition and retention of future customers and our ability to generate revenue, our ability to fund our future operations, risks regarding our intellectual property, risks regarding our ability to maintain the listing of our common stock on Nasdaq, as well as other factors discussed in Shuttle Pharma's SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharma disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Shuttle Pharmaceuticals
Chris Cooper
Chief Executive Officer
info@shuttlepharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289953

FAQ

What did Shuttle Pharmaceuticals (SHPH) announce about molecule.ai on March 26, 2026?

Shuttle Pharmaceuticals announced expanded models and an autonomous AI agent preview for molecule.ai, enabling multi-step reasoning. According to the company, the update adds generative and predictive models, multimodal data handling, and multi-agent orchestration to speed therapeutic discovery workflows.

How will the new autonomous AI agents on molecule.ai affect research teams at SHPH?

The agents are designed to reduce manual effort and increase throughput for research teams by automating discrete tasks. According to the company, agents can ingest multimodal data, use integrated tools, and execute multi-step scientific workflows to boost efficiency.

What capabilities does the molecule.ai update add for therapeutic candidate evaluation at SHPH?

The update adds prioritization and prediction tools to identify gene–disease links and compound–target interactions. According to the company, these capabilities create a more connected framework for earlier, higher-confidence decision-making in discovery.

Does Shuttle Pharmaceuticals say the molecule.ai release will change development timelines for drugs?

Shuttle Pharmaceuticals says the platform could materially reduce timelines, lower costs, and increase success probability across discovery stages. According to the company, integrated reasoning, prediction, and automation drive faster decision-making earlier in development.

Is the autonomous AI agent on molecule.ai available now or still in preview for SHPH?

The company unveiled a preview of its next-generation autonomous AI agent system rather than a final release. According to the company, the preview demonstrates multi-agent orchestration built on frontier AI models and ongoing platform expansion.

How does Shuttle Pharmaceuticals position molecule.ai in the AI-driven drug development market?

Shuttle Positions molecule.ai as an end-to-end, scalable solution moving beyond standalone models to reasoning and automation. According to the company, this evolution places it to play a leading role in next-generation AI-powered biopharma innovation.